Cartesian Therapeutics Reports $39.2 Million Net Loss in Q1 2026

Cartesian Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a significant net loss of $39.2 million, compared to a net loss of $17.7 million for the same period in 2025. The company's total revenues for the quarter were $78,000, a sharp decline from $1.1 million in the previous year, primarily due to the absence of collaboration and license revenue, which had contributed $400,000 in the prior year. Grant revenue also decreased, falling to $78,000 from $700,000, attributed to reduced reimbursable expenses under a grant from the National Institute of Neurological Disorders and Stroke.

Operating expenses for the quarter increased to $26.6 million, up from $23 million in the first quarter of 2025, driven mainly by a 33% rise in research and development costs, which totaled $19.5 million. This increase was largely due to ongoing expenses related to the Phase 3 AURORA trial for the company's lead product candidate, Descartes-08, aimed at treating myasthenia gravis. General and administrative expenses decreased to $7.1 million from $8.3 million, reflecting lower professional and consulting fees.

As of March 31, 2026, Cartesian Therapeutics had cash, cash equivalents, and restricted cash totaling $120.4 million, a decrease from $126.9 million at the end of 2025. The company’s accumulated deficit reached $861.6 million, indicating ongoing financial challenges as it continues to invest heavily in research and development. The company anticipates that operating losses will persist as it advances its clinical programs and seeks regulatory approvals.

In terms of strategic developments, Cartesian Therapeutics entered into a non-exclusive patent license agreement with Biogen in September 2023, which allows for the research and development of engineered T-cell therapies for autoimmune diseases. The company also reported the sale of 2.27 million shares of common stock under its at-the-market equity offering program, generating approximately $14.6 million in net proceeds during the quarter.

Looking ahead, Cartesian Therapeutics expects to continue incurring significant expenses as it progresses its clinical trials and seeks to commercialize its product candidates. The company plans to finance its operations through a combination of equity offerings, debt financing, and collaboration agreements. Management believes that its current cash reserves will support operations for at least the next 12 months, although it acknowledges the need for additional funding to sustain its long-term growth and development objectives.